|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPL15 |
Gene summary for RPL15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPL15 | Gene ID | 6138 |
| Gene name | ribosomal protein L15 | |
| Gene Alias | DBA12 | |
| Cytomap | 3p24.2 | |
| Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | A0A024R2Q4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6138 | RPL15 | GSM4909280 | Human | Breast | Precancer | 4.36e-05 | -3.78e-01 | 0.0305 |
| 6138 | RPL15 | GSM4909282 | Human | Breast | IDC | 2.13e-56 | -2.79e-01 | -0.0288 |
| 6138 | RPL15 | GSM4909285 | Human | Breast | IDC | 2.07e-03 | -8.22e-02 | 0.21 |
| 6138 | RPL15 | GSM4909286 | Human | Breast | IDC | 5.44e-20 | -1.27e-01 | 0.1081 |
| 6138 | RPL15 | GSM4909287 | Human | Breast | IDC | 3.51e-20 | -2.49e-01 | 0.2057 |
| 6138 | RPL15 | GSM4909292 | Human | Breast | IDC | 2.12e-10 | -4.66e-01 | 0.1236 |
| 6138 | RPL15 | GSM4909293 | Human | Breast | IDC | 2.55e-33 | -1.56e-01 | 0.1581 |
| 6138 | RPL15 | GSM4909294 | Human | Breast | IDC | 5.44e-14 | -1.87e-01 | 0.2022 |
| 6138 | RPL15 | GSM4909297 | Human | Breast | IDC | 2.43e-06 | -1.75e-01 | 0.1517 |
| 6138 | RPL15 | GSM4909298 | Human | Breast | IDC | 2.58e-14 | -9.18e-02 | 0.1551 |
| 6138 | RPL15 | GSM4909301 | Human | Breast | IDC | 3.60e-04 | -9.21e-02 | 0.1577 |
| 6138 | RPL15 | GSM4909302 | Human | Breast | IDC | 1.85e-04 | -1.59e-01 | 0.1545 |
| 6138 | RPL15 | GSM4909306 | Human | Breast | IDC | 2.11e-14 | -1.12e-01 | 0.1564 |
| 6138 | RPL15 | GSM4909311 | Human | Breast | IDC | 3.04e-08 | -1.91e-01 | 0.1534 |
| 6138 | RPL15 | GSM4909313 | Human | Breast | IDC | 5.60e-03 | -1.71e-01 | 0.0391 |
| 6138 | RPL15 | GSM4909315 | Human | Breast | IDC | 1.31e-09 | -1.30e-01 | 0.21 |
| 6138 | RPL15 | GSM4909316 | Human | Breast | IDC | 1.97e-05 | -2.64e-01 | 0.21 |
| 6138 | RPL15 | GSM4909317 | Human | Breast | IDC | 3.49e-29 | -2.74e-01 | 0.1355 |
| 6138 | RPL15 | GSM4909318 | Human | Breast | IDC | 2.05e-03 | -2.79e-01 | 0.2031 |
| 6138 | RPL15 | GSM4909319 | Human | Breast | IDC | 2.83e-19 | -3.80e-01 | 0.1563 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
| GO:19908303 | Breast | Precancer | cellular response to leukemia inhibitory factor | 13/1080 | 94/18723 | 2.83e-03 | 2.49e-02 | 13 |
| GO:19908233 | Breast | Precancer | response to leukemia inhibitory factor | 13/1080 | 95/18723 | 3.11e-03 | 2.64e-02 | 13 |
| GO:00973058 | Breast | Precancer | response to alcohol | 25/1080 | 253/18723 | 6.16e-03 | 4.35e-02 | 25 |
| GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
| GO:009730514 | Breast | IDC | response to alcohol | 36/1434 | 253/18723 | 2.29e-04 | 3.64e-03 | 36 |
| GO:00454713 | Breast | IDC | response to ethanol | 21/1434 | 137/18723 | 1.72e-03 | 1.67e-02 | 21 |
| GO:19908301 | Breast | IDC | cellular response to leukemia inhibitory factor | 15/1434 | 94/18723 | 5.06e-03 | 3.79e-02 | 15 |
| GO:199082311 | Breast | IDC | response to leukemia inhibitory factor | 15/1434 | 95/18723 | 5.59e-03 | 4.07e-02 | 15 |
| GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
| GO:009730524 | Breast | DCIS | response to alcohol | 34/1390 | 253/18723 | 5.54e-04 | 7.09e-03 | 34 |
| GO:004547111 | Breast | DCIS | response to ethanol | 20/1390 | 137/18723 | 2.73e-03 | 2.40e-02 | 20 |
| GO:19908302 | Breast | DCIS | cellular response to leukemia inhibitory factor | 15/1390 | 94/18723 | 3.79e-03 | 3.03e-02 | 15 |
| GO:19908232 | Breast | DCIS | response to leukemia inhibitory factor | 15/1390 | 95/18723 | 4.20e-03 | 3.31e-02 | 15 |
| GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
| GO:00973059 | Cervix | CC | response to alcohol | 46/2311 | 253/18723 | 4.40e-03 | 2.69e-02 | 46 |
| GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
| GO:000218125 | Cervix | N_HPV | cytoplasmic translation | 42/534 | 148/18723 | 2.61e-30 | 1.19e-26 | 42 |
| GO:009730515 | Cervix | N_HPV | response to alcohol | 20/534 | 253/18723 | 4.14e-05 | 9.81e-04 | 20 |
| GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPL15 | SNV | Missense_Mutation | c.484C>T | p.Arg162Cys | p.R162C | P61313 | protein_coding | deleterious(0.02) | benign(0.031) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RPL15 | SNV | Missense_Mutation | c.484N>T | p.Arg162Cys | p.R162C | P61313 | protein_coding | deleterious(0.02) | benign(0.031) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| RPL15 | SNV | Missense_Mutation | rs754769885 | c.611N>A | p.Arg204His | p.R204H | P61313 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RPL15 | SNV | Missense_Mutation | c.25N>A | p.Glu9Lys | p.E9K | P61313 | protein_coding | deleterious(0.01) | benign(0.092) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RPL15 | SNV | Missense_Mutation | novel | c.583C>T | p.Arg195Cys | p.R195C | P61313 | protein_coding | tolerated(0.12) | benign(0.014) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL15 | SNV | Missense_Mutation | novel | c.577N>G | p.Arg193Gly | p.R193G | P61313 | protein_coding | deleterious(0.04) | benign(0.079) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL15 | SNV | Missense_Mutation | novel | c.467N>G | p.His156Arg | p.H156R | P61313 | protein_coding | deleterious(0.02) | benign(0.031) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| RPL15 | SNV | Missense_Mutation | novel | c.284C>T | p.Ala95Val | p.A95V | P61313 | protein_coding | tolerated(0.16) | benign(0.005) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPL15 | SNV | Missense_Mutation | novel | c.407A>G | p.Asp136Gly | p.D136G | P61313 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| RPL15 | SNV | Missense_Mutation | novel | c.181N>G | p.Ile61Val | p.I61V | P61313 | protein_coding | tolerated(0.39) | benign(0.045) | TCGA-G3-A3CG-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Targeted Molecular therapy | sorafenib | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |